# Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma

> **NCT02899195** · PHASE2 · COMPLETED · sponsor: **PrECOG, LLC.** · enrollment: 55 (actual)

## Conditions studied

- Mesothelioma
- Pleural Mesothelioma

## Interventions

- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT02899195
- **Lead sponsor:** PrECOG, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-13
- **Primary completion:** 2020-02-16
- **Final completion:** 2023-06-29
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2023-07-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02899195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02899195, "Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02899195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*